Avian Influenza Virus Type A H7N9 subtype antibody and antigen (recombinant protein)

Diagnostic anti-Avian Influenza Virus Type A H7N9 subtype antibodies pairs and antigen for animal health (animal Avian/Bird/Poultry infectious disease Avian influenza) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Avian/Bird/Poultry disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P214-Ag01 Recombinant Avian Influenza Virus Type A H7N9 subtype protein $3090.00
GMP-VT-P214-Ab01 Anti-Avian Influenza Virus Type A H7N9 subtype mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P214-Ab02 Anti-Avian Influenza Virus Type A H7N9 subtype mouse monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P214-Ag01
Product Name Recombinant Avian Influenza Virus Type A H7N9 subtype protein
Pathogen Avian Influenza Virus Type A H7N9 subtype
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Avian Influenza Virus Type A H7N9 subtype antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Avian Influenza Virus Type A H7N9 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Tag His
Product description Recombinant Avian Influenza Virus Type A H7N9 subtype proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P214-Ab01,GMP-VT-P214-Ab02
Pathogen Avian Influenza Virus Type A H7N9 subtype
Product Name Anti-Avian Influenza Virus Type A H7N9 subtype mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Avian Influenza Virus Type A H7N9 subtype antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H7N9 subtype antibodies in Avian Influenza Virus Type A H7N9 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Product description Anti-Avian Influenza Virus Type A H7N9 subtype mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H7N9 subtype antibodies./td>
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen


    Influenza A Virus Subtype H7N9: A Detailed Exploration

    Introduction:

    Influenza A Virus Subtype H7N9, a pathogen of immense significance, represents a subgroup of influenza A viruses that has garnered substantial attention due to its zoonotic potential and capacity to cause severe respiratory infections in both avian and human populations. In this comprehensive exploration, we delve into the classification, structure, hosts, associated diseases, and diagnostic methods of this virus to provide a detailed understanding of its biological characteristics.

    Classification:

    Influenza A Virus Subtype H7N9 belongs to the Orthomyxoviridae family, which encompasses a diverse range of viruses. These viruses are characterized by their single-stranded, negative-sense RNA genome, and the Influenza A genus, to which H7N9 belongs, is well-known for its ability to undergo frequent antigenic changes, resulting in the emergence of new strains. This genetic plasticity is a key factor contributing to the virus's pathogenicity and its ability to evade pre-existing immunity in the host population.

    Viral Structure:

    The genomic structure of Influenza A Virus Subtype H7N9 is both intriguing and complex. It consists of eight RNA segments, each coding for specific proteins essential for its replication and interaction with host cells. Of particular significance are the hemagglutinin (H7) and neuraminidase (N9) genes. Hemagglutinin plays a crucial role in viral attachment to host cell receptors, while neuraminidase facilitates the release of newly formed viral particles from infected cells. These surface glycoproteins are responsible for the virus's antigenic identity, defining its subtype and influencing its virulence.

    Hosts and Associated Diseases:

    The natural reservoir for Influenza A Virus Subtype H7N9 primarily comprises avian species, with chickens and ducks being the primary carriers. These avian hosts play a pivotal role in the perpetuation and evolution of the virus. However, what makes H7N9 particularly concerning is its ability to cross the species barrier and infect humans. Such zoonotic transmission events have resulted in sporadic human cases with severe respiratory manifestations.

    In humans, infection with H7N9 can lead to a wide spectrum of clinical presentations, ranging from mild respiratory symptoms to severe pneumonia and acute respiratory distress syndrome. Severe cases are associated with high mortality rates, underscoring the importance of monitoring and controlling the spread of this virus, particularly in regions where human infections have been reported.

    Diagnostic Methods, Including Nucleic Acids:

    Accurate and timely diagnosis of Influenza A Virus Subtype H7N9 is crucial for public health surveillance and outbreak management. Diagnostic methods have evolved significantly in recent years, with a strong focus on molecular techniques that enable the precise detection and characterization of the virus.

    Nucleic acid-based methods are the cornerstone of H7N9 diagnostics. These techniques involve the detection of specific viral genes using polymerase chain reaction (PCR) assays. Key targets for detection include the H7 and N9 genes, which are unique to this subtype, and the Matrix (M) gene, which is used for universal detection of influenza A viruses. PCR amplifies viral RNA segments, allowing for the identification of H7N9 with high specificity and sensitivity.

    Moreover, real-time reverse transcription PCR (rRT-PCR) assays have been developed to provide rapid results, enabling healthcare professionals to swiftly identify and respond to suspected cases. These methods are essential in monitoring and responding to H7N9 outbreaks, as they allow for early detection and intervention, reducing the potential for wider transmission in both avian and human populations.

    In conclusion, Influenza A Virus Subtype H7N9 represents a dynamic and evolving viral entity with the potential to cause severe disease in both avian and human hosts. Understanding its classification, genetic structure, host range, associated diseases, and diagnostic methods is crucial for public health preparedness and response. Continued research and vigilance are essential to monitor and mitigate the impact of this virus on global health.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.